Interested participants can access the live discussion by dialing (888) 210-2654 in the U.S. or (646) 960-0278 for international callers, using the access code 7862189. A live webcast will also be available through the company’s investor relations portal at www.insmed.com. For those unable to attend, a replay will be accessible one hour after the event concludes until August 13, 2026, by calling (800) 770-2030 or (609) 800-9909 with the same access code. The archived webcast will remain available on the company website for 90 days.
Insmed continues to focus on its core therapeutic areas: respiratory, immunology, inflammation, and neuro-rare diseases. The company currently manages a portfolio that includes two approved therapies for chronic lung conditions alongside an active research pipeline utilizing technologies such as gene therapy and AI-driven protein engineering.
Comments (0)
No comments yet. Be the first!